Physician profile
Stephen Pan
NPI 1952581779
$158,686.16
in general payments reported to CMS, 2019-2025
19 companies · $75K in 2025
The $75K reported for 2025 was more than what 96% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,281 · 2020: $11K · 2021: $2,795 · 2022: $11K · 2023: $20K · 2024: $39K · 2025: $75K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $114K · Consulting Fee: $13K · Food and Beverage: $3,391 · Travel and Lodging: $2,576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $114,110.29 |
| Consulting Fee | $13,230.00 |
| Food and Beverage | $3,390.50 |
| Travel and Lodging | $2,575.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $61,826.19 | 2019-2025 | Amvuttra |
| Pfizer INC. | $54,978.91 | 2019-2025 | |
| Bridgebio Pharma, INC. | $24,241.15 | 2025 | Attruby |
| Akcea Therapeutics, INC. | $7,563.93 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $4,514.33 | 2019-2025 | Wainua |
| Pfizer International LLC | $3,780.00 | 2022 | |
| Vifor Pharma, INC. | $918.93 | 2019 | |
| Abbott Laboratories | $195.72 | 2019-2022 | |
| Sobi, INC | $150.00 | 2023 | |
| Merck Sharp & Dohme LLC | $123.13 | 2022-2025 | Verquvo |
| Daxor Corporation | $101.56 | 2024 | Bva-100 |
| Abiomed | $74.88 | 2024 | Impella |
| Novartis Pharmaceuticals Corporation | $72.25 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $60.88 | 2023-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $37.27 | 2022-2023 | Camzyos |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $19.38 | 2021 | |
| Chiesi USA, INC. | $14.96 | 2021 | |
| Gilead Sciences, INC. | $12.69 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Pan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.